Clinical Trial Update: Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenvatinib plus sintilimab with or without DEB-TACE and hepatic arterial infusion chemotherapy for non-resectable hepatocellular carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Tyvyt (Sintilimab)

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 2 | Status: RECRUITING